Dynavax(DVAX)

Search documents
Dynavax to Present at Upcoming Investor Conferences
prnewswire.com· 2024-05-28 20:18
EMERYVILLE, Calif. , May 28, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June: William Blair 44th Annual Growth Stock Conference on Tuesday, June 4 at 1:20 p.m. CT Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10 at 4:00 p.m. ET The presentations will ...
Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.
Prnewswire· 2024-05-14 12:30
EMERYVILLE, Calif., May 14, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today provided a regulatory update for the Company's supplemental Biologics License Application (sBLA) to include a four-dose HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted] regimen for adults on hemodialysis. The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to the sBLA, stating that the application did not provide sufficient data to support ...
Dynavax(DVAX) - 2024 Q1 - Earnings Call Transcript
2024-05-08 23:51
Dynavax Technologies Corporation (NASDAQ:DVAX) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Paul Cox - VP, Investor Relations & Corporate Communications Ryan Spencer - CEO Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Rita O'Connor - Interim CFO Conference Call Participants Matthew Phipps - William Blair Paul Choi - Goldman Sachs Ed White - H.C. Wainwright Phil Nadeau - TD Cowen Roy Buchanan - Citizens JMP Operator Welcome to the Dynavax Technolog ...
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research· 2024-05-08 22:21
Dynavax Technologies (DVAX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -40%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.01 per share when it actually produced break-even earnings, delivering a surprise of 100%.Over the last four quarters, t ...
Dynavax(DVAX) - 2024 Q1 - Quarterly Report
2024-05-08 20:10
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-34207 Dynavax Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 33-0728374 (State or o ...
Dynavax(DVAX) - 2024 Q1 - Quarterly Results
2024-05-08 20:05
Exhibit 99.1 Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates EMERYVILLE, CA – May 8, 2024 – Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended March 31, 2024. "The first quarter of 2024 saw continued year-over-year growth in quarterly HEPLISAV-B net product revenue. As we expected, growth in the ...
Dynavax Technologies: Still A Believer
Seeking Alpha· 2024-03-24 11:39
Gilnature Shares of vaccine maker Dynavax Technologies Corporation (NASDAQ:DVAX) continue to trade at the lower end of a $12 to $15 range, which they have more or less maintained since mid-June 2023. The company's core asset (HEPISLAV-B) saw FY23 sales improve 69% over FY22 to $213.3 million, making the company cash flow positive despite the loss of revenue from CpG 1018 in Covid-19 vaccines. With three more CpG 1018 vaccine candidates advancing to or posting data from mid-stage trials in 2024 and HEPIS ...
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
Prnewswire· 2024-02-27 23:54
EMERYVILLE, Calif., Feb. 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at TD Cowen's 44th Annual Health Care Conference on Monday, March 4 at 10:30 a.m. ET. The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/even ...
Dynavax(DVAX) - 2023 Q4 - Earnings Call Transcript
2024-02-23 00:34
Dynavax Technologies Corporation (NASDAQ:DVAX) Q4 2023 Earnings Conference Call February 22, 2024 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - Chief Executive Officer Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - Chief Financial Officer Conference Call Participants Matthew Phipps - William Blair Jonathan Miller - Evercore ISI Paul Choi - Goldman Sachs Ernesto Rodriguez-Dumont - Cowen Roy ...
Dynavax Technologies (DVAX) Reports Break-Even Earnings for Q4
Zacks Investment Research· 2024-02-22 23:16
Dynavax Technologies (DVAX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 100%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.01 per share when it actually produced earnings of $0.10, delivering a surprise of 1,100%.Over the last four quarters ...